APA

Ennishi D., Takeuchi K., Yokoyama M., Asai H., Mishima Y., Terui Y., Takahashi S., Komatsu H., Ikeda K., Yamaguchi M., Suzuki R., Tanimoto M. & Hatake K. (20081104). CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, Takahashi S, Komatsu H, Ikeda K, Yamaguchi M, Suzuki R, Tanimoto M and Hatake K. 20081104. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Ennishi D., Takeuchi K., Yokoyama M., Asai H., Mishima Y., Terui Y., Takahashi S., Komatsu H., Ikeda K., Yamaguchi M., Suzuki R., Tanimoto M. and Hatake K. (20081104). CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, Takahashi S, Komatsu H, Ikeda K, Yamaguchi M, Suzuki R, Tanimoto M and Hatake K. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. : Annals of oncology : official journal of the European Society for Medical Oncology. 20081104.